Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1333842 | 0.91 | CNR2 (0.76) | CNR2CNR1 | |
| SCHEMBL1336160 | 0.90 | CNR2 (0.85) | CNR2CNR1 | |
| SCHEMBL1333751 | 0.85 | CNR2 (0.79) | CNR2CNR1 | |
| SCHEMBL1335925 | 0.84 | CNR2 (0.81) | CNR2CNR1 | |
| SCHEMBL1333946 | 0.78 | CNR2 (0.73) | CNR2CNR1 | |
| SCHEMBL1335992 | 0.78 | CNR2 (0.73) | CNR2CNR1 | |
| SCHEMBL1333943 | 0.78 | CNR2 (0.73) | CNR2CNR1 | |
| SCHEMBL3999423 | 0.78 | CNR2 (0.72) | CNR2CNR1 | |
| SCHEMBL1336074 | 0.76 | CNR2 (0.81) | CNR2CNR1 | |
| SCHEMBL1336166 | 0.76 | CNR2 (0.79) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8653063-B2 | N-substituted saturated heterocyclic sulfone compounds with CB2 receptor agonistic activity | RAQUALIA PHARMA INC. (JP) | 2014-02-18 | — | — | US | disclosed |
| US-8653063-B2 | N-substituted saturated heterocyclic sulfone compounds with CB2 receptor agonistic activity | RAQUALIA PHARMA INC. (JP) | 2014-02-18 | — | — | US | disclosed |
| US-8653063-B2 | N-substituted saturated heterocyclic sulfone compounds with CB2 receptor agonistic activity | RAQUALIA PHARMA INC. (JP) | 2014-02-18 | — | — | US | disclosed |
| US-20110281840-A1 | N-SUBSTITUTED SATURATED HETEROCYCLIC SULFONE COMPOUNDS WITH CB2 RECEPTOR AGONISTIC ACTIVITY | ASKAT INC. (JP) | 2011-11-17 | — | — | US | disclosed |
| US-20110281840-A1 | N-SUBSTITUTED SATURATED HETEROCYCLIC SULFONE COMPOUNDS WITH CB2 RECEPTOR AGONISTIC ACTIVITY | ASKAT INC. (JP) | 2011-11-17 | — | — | US | disclosed |
| US-20110281840-A1 | N-SUBSTITUTED SATURATED HETEROCYCLIC SULFONE COMPOUNDS WITH CB2 RECEPTOR AGONISTIC ACTIVITY | ASKAT INC. (JP) | 2011-11-17 | — | — | US | disclosed |
| EP-2379533-A1 | N-SUBSTITUTED SATURATED HETEROCYCLIC SULFONE COMPOUNDS WITH CB2 RECEPTOR AGONISTIC ACTIVITY | RaQualia Pharma Inc (JP) | 2011-10-26 | — | — | EP | disclosed |
| WO-2010084767-A1 | N-SUBSTITUTED SATURATED HETEROCYCLIC SULFONE COMPOUNDS WITH CB2 RECEPTOR AGONISTIC ACTIVITY | RAQUALIA PHARMA INC. (JP) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281840-A1 | N-SUBSTITUTED SATURATED HETEROCYCLIC SULFONE COMPOUNDS WITH CB2 RECEPTOR AGONISTIC ACTIVITY | CNR1, CNR2, NPSR1 | CNR2 2/4885CNR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.